Quoin Pharmaceuticals

Quoin Pharmaceuticals is pleased to announce our fourth quarter and 2024 full-year results. 2024 was without a doubt the most significant year in Quoin’s history. This progress was particularly exemplified in the clinical development of QRX003, our product candidate for Netherton Syndrome, and we are encouraged by the positive data our ongoing studies are generating. Read more here:?https://bit.ly/4bQ5bMt ?#nethertonsyndrome #QNRX #financialresults

Carmon McTigue’s son, Silas, was born with Netherton Syndrome. At first, doctors only guessed about which disease her son had, leaving Carmon and her husband with no definitive answers about their son’s condition. Silas suffered from failure to thrive multiple times and was hospitalized 15-20 times in his first years of life due to severe infections. After seven months and consultations with dozens of specialists her son was finally properly diagnosed with Netherton Syndrome. From the moment he was born, Silas faced an uphill battle. Netherton Syndrome isn’t just a skin condition—it’s a daily struggle with pain, inflammation, and uncertainty. There is no approved treatment. No cure. Yet despite it all, Silas keeps moving forward. This past year, he took on another challenge—playing football for the first time. With extra precautions and a determined spirit, he stepped onto the field, proving that while Netherton Syndrome is a part of his life, it does not define him. For Silas and so many others, the fight continues—not just for resilience, but for real solutions. A treatment for Netherton Syndrome is desperately needed. Watch his journey and join us in raising awareness and support for the Netherton Syndrome community.? #netherton #QNRX #nethertonsyndrome #nethertonsyndromecommunity Quoin Pharmaceuticals https://lnkd.in/eVMseTfP

Quoin Pharmaceuticals is pleased to announce the filing of US and International patent applications for novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare diseases including microcystic lymphatic malformations, venous malformations and angiofibromas.?Read more here:?https://bit.ly/3DcqB9P? #QNRX #rarediseases #patent?

At Quoin Pharmaceuticals, we believe that rare diseases are only rare if you don’t live with one. Today, on Rare Disease Day, we are proud to debut the first episode of our NETHERTON NOW "Living with Netherton" video series—a powerful initiative aimed at shedding light on the profound and often misunderstood impact of Netherton Syndrome. This first episode features Carmon McTigue, whose son was born with Netherton Syndrome, a devastating genetic disorder that remains largely unknown. Carmon shares the emotional journey of navigating misdiagnoses, hospitalizations, and the harsh reality that no approved treatment or cure exists. Her story reflects the resilience, strength, and determination of families who face this disease every day. Through the NETHERTON NOW campaign, Quoin is committed to raising awareness, advocacy, and education for this underserved community. Future episodes will continue to highlight patient and family experiences, emphasizing the urgent need for greater research and treatment options. At Quoin, we are working to change this reality. We are currently conducting four clinical trials to evaluate QRX003, our lead candidate for Netherton Syndrome. Our mission is clear: to provide hope where there has been none and to deliver a treatment for this neglected disease. We extend our deepest gratitude to the McTigue family for sharing their story and helping us bring visibility to this condition. Their voices—and those of countless others in the rare disease community—deserve to be heard. hashtag #rarediseaseday2025 Watch the full episode here: https://lnkd.in/e8JDt9Wv Learn more about our clinical trials: https://lnkd.in/gGaJ4xnZ https://lnkd.in/eNJzVNV8

Quoin Pharmaceuticals is pleased to announce the global premiere of the “NETHERTON NOW” video series?with first episode?set to launch on Rare Disease Day,?this Friday - February 28, 2025. This series is dedicated?to?giving a voice to?the?patients?and families directly affected by?Netherton Syndrome. Read more:?https://bit.ly/41v42X2? #netherton #QNRX #rarediseaseday ?

As Rare Disease Day approaches, we recognize the urgent need for breakthrough treatments for conditions like Netherton Syndrome (NS)—a rare, life-threatening genetic disorder with no FDA-approved therapies. Currently, we are conducting four ongoing clinical studies evaluating QRX003’s safety and efficacy as a potential first-in-class treatment for NS. With each study, we move closer to delivering a breakthrough therapy for the Netherton community. It is time to bring hope where there is currently none. Find out more:?https://bit.ly/412BPph hashtag #Rarediseaseday2025 #NETHERTONNOW

Rare Disease Day on February 28, 2025, is a critical reminder that while individual rare diseases may be uncommon, together they impact over?300 million people worldwide. For those living with?Netherton Syndrome—a devastating genetic condition with no approved treatment—awareness and advocacy are crucial to driving research and progress. Through?NETHERTON?NOW, Quoin’s initiative dedicated to supporting the Netherton Syndrome community, we are committed to amplifying voices, supporting patients, and pushing for meaningful change. At Quoin, we know?rare diseases are only rare if you don’t live with one? This Rare Disease Day, we stand with patients and families in the fight for better treatments, greater awareness, and a brighter future. Because everyone deserves to feel comfortable in their own skin Visit us at?https://nethertonnow.com?#Rarediseaseday2025 #NETHERTONNOW

Quoin Pharmaceuticals is pleased to announce the launch of ‘NETHERTON NOW’, a multi-pronged media campaign to raise awareness of the rare disease Netherton Syndrome and its impact on patients, family members and caregivers. Read more here:?https://bit.ly/42HP4y3?#nethertonsyndrome #QNRX #nethertonnow #QRX003

Quoin Pharmaceuticals is pleased to announce further clinical evidence of QRX003 effectiveness in Netherton Syndrome. This data set has provided the clearest clinical evidence to date that the active ingredient in QRX003 is a competitive broad spectrum serine protease inhibitor and the discontinuation of treatment with QRX003 results in a complete reversal of all clinical benefits derived from continued treatment with the product. Read more here:?https://bit.ly/40wds2S? #nethertonsyndrome #QNRX #clinicaltrials

Quoin Pharmaceuticals is pleased to announce additional positive interim data from its ongoing open-label Netherton Syndrome study for its first subject dosed twice daily with QRX003 which demonstrated clinical benefits observed across all measured endpoints. Read more here:?https://bit.ly/4a4IkvK ?#QNRX #nethertonsyndrome #QRX003 #positivedata